These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 24216013)
1. [Risk of pharmacological interactions due to the co-administration of statins and cytochrome P450 isoenzyme 3A4-metabolized drugs: multicentre, crossover study]. Mostaza JM; Lahoz C; Morales-Olivas F; Pinto X; Tranche S; Suarez-Tembra M; Mantilla T; Rius J Med Clin (Barc); 2014 Nov; 143(10):427-32. PubMed ID: 24216013 [TBL] [Abstract][Full Text] [Related]
2. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Bakhai A; Rigney U; Hollis S; Emmas C Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927 [TBL] [Abstract][Full Text] [Related]
3. Statin medication in patients treated with antiepileptic drugs in Norway. Gedde-Dahl A; Devold HM; Molden E Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):881-5. PubMed ID: 22529023 [TBL] [Abstract][Full Text] [Related]
4. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. Kerr KP; Mate KE; Magin PJ; Marley J; Stocks NP; Disler P; Pond CD J Clin Pharm Ther; 2014 Aug; 39(4):383-9. PubMed ID: 24702306 [TBL] [Abstract][Full Text] [Related]
5. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Devold HM; Molden E; Skurtveit S; Furu K Br J Clin Pharmacol; 2009 Feb; 67(2):234-41. PubMed ID: 19220274 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030 [TBL] [Abstract][Full Text] [Related]
7. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Li DQ; Kim R; McArthur E; Fleet JL; Bailey DG; Juurlink D; Shariff SZ; Gomes T; Mamdani M; Gandhi S; Dixon S; Garg AX CMAJ; 2015 Feb; 187(3):174-180. PubMed ID: 25534598 [TBL] [Abstract][Full Text] [Related]
8. Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction. Gulec S; Ozdol C; Rahimov U; Atmaca Y; Kumbasar D; Erol C J Invasive Cardiol; 2005 Nov; 17(11):589-93. PubMed ID: 16264203 [TBL] [Abstract][Full Text] [Related]
9. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Neuvonen PJ; Niemi M; Backman JT Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259 [TBL] [Abstract][Full Text] [Related]
10. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Vinholt P; Poulsen TS; Korsholm L; Kristensen SR; Hallas J; Damkier P; Mickley H Thromb Haemost; 2005 Aug; 94(2):438-43. PubMed ID: 16113837 [TBL] [Abstract][Full Text] [Related]
11. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study. Tirkkonen T; Ryynänen A; Vahlberg T; Irjala K; Klaukka T; Huupponen R; Laine K Drug Saf; 2008; 31(3):231-40. PubMed ID: 18302447 [TBL] [Abstract][Full Text] [Related]
12. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. Blagojevic A; Delaney JA; Lévesque LE; Dendukuri N; Boivin JF; Brophy JM Pharmacoepidemiol Drug Saf; 2009 May; 18(5):362-9. PubMed ID: 19253920 [TBL] [Abstract][Full Text] [Related]
14. Co-medication of statins with contraindicated drugs. Yang BR; Seong JM; Choi NK; Shin JY; Lee J; Kim YJ; Kim MS; Park S; Song HJ; Park BJ PLoS One; 2015; 10(5):e0125180. PubMed ID: 25932626 [TBL] [Abstract][Full Text] [Related]
15. Suboptimal choices and dosing of statins at start of therapy. Mantel-Teeuwisse AK; Klungel OH; Schalekamp T; Verschuren WM; Porsius AJ; de Boer A Br J Clin Pharmacol; 2005 Jul; 60(1):83-9. PubMed ID: 15963098 [TBL] [Abstract][Full Text] [Related]
16. Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study. Wang YC; Hsieh TC; Chou CL; Wu JL; Fang TC Medicine (Baltimore); 2016 Jan; 95(2):e2487. PubMed ID: 26765458 [TBL] [Abstract][Full Text] [Related]
17. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Geisler T; Zürn C; Paterok M; Göhring-Frischholz K; Bigalke B; Stellos K; Seizer P; Kraemer BF; Dippon J; May AE; Herdeg C; Gawaz M Eur Heart J; 2008 Jul; 29(13):1635-43. PubMed ID: 18503057 [TBL] [Abstract][Full Text] [Related]
18. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. Saw J; Brennan DM; Steinhubl SR; Bhatt DL; Mak KH; Fox K; Topol EJ; J Am Coll Cardiol; 2007 Jul; 50(4):291-5. PubMed ID: 17659194 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Clopidogrel Co-administered With Statins and Proton Pump Inhibitors: A Korean National Health Insurance Database Study. Kim MS; Song HJ; Lee J; Yang BR; Choi NK; Park BJ Clin Pharmacol Ther; 2019 Jul; 106(1):182-194. PubMed ID: 30648733 [TBL] [Abstract][Full Text] [Related]
20. Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention. Park JS; Cha KS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Kim HS; Heart Vessels; 2017 Jun; 32(6):690-699. PubMed ID: 27904973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]